PE20220704A1 - Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos - Google Patents
Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticosInfo
- Publication number
- PE20220704A1 PE20220704A1 PE2022000148A PE2022000148A PE20220704A1 PE 20220704 A1 PE20220704 A1 PE 20220704A1 PE 2022000148 A PE2022000148 A PE 2022000148A PE 2022000148 A PE2022000148 A PE 2022000148A PE 20220704 A1 PE20220704 A1 PE 20220704A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- pyridazin
- diamino
- proapoptotic agents
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Referido a un compuesto de formula (I) en donde: R1 y R2, independientemente uno de otro, representan un grupo seleccionado de: H; alquiloC1-C6 lineal o ramificado sustituido opcionalmente con un grupo hidroxilo o un grupo alcoxiC1-C6, entre otros; R3 representa un grupo seleccionado de: hidrogeno; cicloalquiloC3-C6; alquiloC1-C6 lineal o ramificado, entre otros. Un compuesto seleccionado es Acido 2-({6-[(1,3-benzotiazol-2-il)amino]-5-metilpiridazin-3-il}(4-hidroxibutil)amino)-5-(3-{2-fluoro-4-[3-(metilamino)prop-1-in-1-il]fenoxi}propil)-1,3-tiazol-4-carboxilico. Estos compuestos derivados de 3,6-diamino-piridazin-3-ilo son agentes proapoptoticos, inhibidores potentes selectivos de Bcl-xL. Tambien se refiere a compuestos intermedios, metodo de preparacion de los mismos, a una composicion farmaceutica que comprende dicho compuesto, una sal de adicion del mismo con un acido o base farmaceuticamente aceptable en combinacion con uno o mas excipientes farmaceuticamente aceptables, y su uso en el tratamiento del cancer o enfermedades autoinmunes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19188747 | 2019-07-29 | ||
| PCT/EP2020/071179 WO2021018857A1 (en) | 2019-07-29 | 2020-07-28 | 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220704A1 true PE20220704A1 (es) | 2022-05-04 |
Family
ID=67514281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000148A PE20220704A1 (es) | 2019-07-29 | 2020-07-28 | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20220289734A1 (es) |
| EP (1) | EP4003988A1 (es) |
| JP (1) | JP7646626B2 (es) |
| KR (1) | KR20220042182A (es) |
| CN (1) | CN114450283B (es) |
| AR (1) | AR119493A1 (es) |
| AU (1) | AU2020322072A1 (es) |
| BR (1) | BR112022001330A2 (es) |
| CA (1) | CA3148502A1 (es) |
| CL (1) | CL2021003594A1 (es) |
| CO (1) | CO2022000700A2 (es) |
| CR (1) | CR20220014A (es) |
| DO (1) | DOP2022000015A (es) |
| GE (1) | GEP20247670B (es) |
| IL (1) | IL289932A (es) |
| JO (1) | JOP20220006A1 (es) |
| MX (1) | MX2022001161A (es) |
| PE (1) | PE20220704A1 (es) |
| PH (1) | PH12022550018A1 (es) |
| TW (1) | TW202118761A (es) |
| UY (1) | UY38809A (es) |
| WO (1) | WO2021018857A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230143605A (ko) * | 2020-11-24 | 2023-10-12 | 노파르티스 아게 | Bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법 |
| KR20230170644A (ko) * | 2021-02-02 | 2023-12-19 | 르 라보레또레 쎄르비에르 | 선택적 bcl-xl protac 화합물 및 사용 방법 |
| EP4525926A1 (en) | 2022-05-20 | 2025-03-26 | Novartis AG | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| KR20250027285A (ko) | 2022-05-20 | 2025-02-25 | 노파르티스 아게 | 항신생물 화합물의 항체-약물 접합체 및 그의 사용 방법 |
| WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1467736A2 (en) | 2001-12-21 | 2004-10-20 | Bayer Pharmaceuticals Corporation | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives |
| WO2009020603A2 (en) * | 2007-08-08 | 2009-02-12 | The Scripps Research Institute | Upp amphiphilic alpha-helix mimetics |
| AU2008343932B2 (en) * | 2007-12-19 | 2013-08-15 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| FR3015483B1 (fr) | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP3305785B1 (en) * | 2015-05-29 | 2021-08-25 | Teijin Pharma Limited | Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof |
-
2020
- 2020-07-27 AR ARP200102095A patent/AR119493A1/es unknown
- 2020-07-28 US US17/630,655 patent/US20220289734A1/en active Pending
- 2020-07-28 GE GEAP202015866A patent/GEP20247670B/en unknown
- 2020-07-28 PE PE2022000148A patent/PE20220704A1/es unknown
- 2020-07-28 CR CR20220014A patent/CR20220014A/es unknown
- 2020-07-28 CA CA3148502A patent/CA3148502A1/en active Pending
- 2020-07-28 UY UY0001038809A patent/UY38809A/es unknown
- 2020-07-28 KR KR1020227006624A patent/KR20220042182A/ko active Pending
- 2020-07-28 JO JOP/2022/0006A patent/JOP20220006A1/ar unknown
- 2020-07-28 TW TW109125418A patent/TW202118761A/zh unknown
- 2020-07-28 JP JP2022505602A patent/JP7646626B2/ja active Active
- 2020-07-28 EP EP20749833.8A patent/EP4003988A1/en active Pending
- 2020-07-28 MX MX2022001161A patent/MX2022001161A/es unknown
- 2020-07-28 WO PCT/EP2020/071179 patent/WO2021018857A1/en active Application Filing
- 2020-07-28 BR BR112022001330A patent/BR112022001330A2/pt unknown
- 2020-07-28 CN CN202080068042.2A patent/CN114450283B/zh active Active
- 2020-07-28 PH PH1/2022/550018A patent/PH12022550018A1/en unknown
- 2020-07-28 AU AU2020322072A patent/AU2020322072A1/en active Pending
-
2021
- 2021-12-30 CL CL2021003594A patent/CL2021003594A1/es unknown
-
2022
- 2022-01-17 IL IL289932A patent/IL289932A/en unknown
- 2022-01-25 DO DO2022000015A patent/DOP2022000015A/es unknown
- 2022-01-26 CO CONC2022/0000700A patent/CO2022000700A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021018857A1 (en) | 2021-02-04 |
| JP2022542937A (ja) | 2022-10-07 |
| GEP20247670B (en) | 2024-09-25 |
| CN114450283A (zh) | 2022-05-06 |
| CO2022000700A2 (es) | 2022-02-07 |
| KR20220042182A (ko) | 2022-04-04 |
| CL2021003594A1 (es) | 2022-11-18 |
| MX2022001161A (es) | 2022-02-22 |
| JOP20220006A1 (ar) | 2023-01-30 |
| EP4003988A1 (en) | 2022-06-01 |
| UY38809A (es) | 2021-02-26 |
| TW202118761A (zh) | 2021-05-16 |
| US20220289734A1 (en) | 2022-09-15 |
| CN114450283B (zh) | 2024-05-07 |
| CA3148502A1 (en) | 2021-02-04 |
| JP7646626B2 (ja) | 2025-03-17 |
| PH12022550018A1 (en) | 2022-10-17 |
| DOP2022000015A (es) | 2022-05-15 |
| IL289932A (en) | 2022-03-01 |
| CR20220014A (es) | 2022-03-02 |
| AU2020322072A1 (en) | 2022-02-10 |
| AR119493A1 (es) | 2021-12-22 |
| BR112022001330A2 (pt) | 2022-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220704A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos | |
| PE20220705A1 (es) | Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin y compuestos relacionados como inhibidores de proteina bcl-xl y agentes proapoptoticos para el tratamiento del cancer | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| PE20230239A1 (es) | Derivado de arilamida con actividad antitumoral | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| AR065464A1 (es) | Derivados de nicotinamida. composiciones farmaceuticas | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR056762A1 (es) | (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos | |
| AR057855A1 (es) | Derivados de pirazina y composicion farmaceutica | |
| AR056574A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| AR058180A1 (es) | Indeno derivados, su preparacion y su uso como medicamentos | |
| AR074608A1 (es) | Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas | |
| PE20211769A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
| AR062737A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento | |
| PE20200445A1 (es) | Inhibidores pirazolicos de magl | |
| PE20230235A1 (es) | Compuestos para modular la actividad de fxr y usos de los mismos | |
| PE20190964A1 (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica | |
| PE20240652A1 (es) | Compuestos que inhiben la isoforma alfa de pi3k y metodos para tratar el cancer | |
| AR060064A1 (es) | Compuestos sustituidos de tetrahidroisoquinolina, su preparacion y su uso en medicamentos para el tratamiento de enfermedades mediadas por los receptores 5-ht6 | |
| UY28688A1 (es) | Derivados de amida | |
| PE20232047A1 (es) | Quinolinas y azaquinolinas como inhibidores de cd38 | |
| PE20232044A1 (es) | Compuestos heterociclicos de heteroarilo y usos de los mismos |